Phase 3 N=542 Randomized Prevention

Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers

Japanese Encephalitis · Measles · Mumps · Rubella

Bottom Line

View on ClinicalTrials.gov: NCT01188343 ↗

Enrolled (actual)

542

Serious AEs

8.1%

Results posted

Aug 2014

Primary outcome: Primary: Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination — 97.9; NA; 96.9; NA Percentage of Participants

Study Design & Population

Study type: Interventional
Phase: Phase 3
Interventions: Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus (Biological)
Age: Pediatric · 0+ yrs
Sex: All
Sponsor: Sanofi Pasteur, a Sanofi Company
Primary completion: Jul 2012

Outcome Measures

Outcome	Result	p-value
PRIMARY Percentage of Participants With Seroconversion to Vaccine Antigens Following Concomitant Administration of Japanese Encephalitis Chimeric Virus Vaccine (JECV) and MMR or Single Administration of JE-CV and MMR Vaccine at 42 Days Following First Vaccination	97.9; NA; 96.9; NA; 97.6; 100	—
SECONDARY Percentage of Participants With Seroconversion to JE-CV and MMR Antigens Before and 42 Days Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine	0.0; 0.0; 0.0; 97.9; 100.0; 96.9	—
SECONDARY Number of Participants With Seroprotection to JE-CV and MMR Antigens Before, at Month 6 After Last Vaccination and Month 12 After First Following Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine	2; 10; 4; 92; 190; 203	—
SECONDARY Geometric Mean Titers of Antibodies to Vaccine Antigens Before and After Concomitant Administration of JE-CV and MMR or Single Administration of JE-CV and MMR Vaccine	5.00; 5.00; 5.00; 510; 581; 332	—
SECONDARY Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of JE-CV Vaccine	18; 30; 35; 0; 0; 0	—
SECONDARY Number of Participants Reporting Solicited Injection Site and Systemic Reactions Following Administration of MMR Vaccine	16; 32; 36; 0; 0; 0	—

Summary

This study is designed to compare the immunogenicity of Japanese encephalitis chimeric virus vaccine (JE-CV) and measles-mumps-rubella (MMR)vaccine when given together or when given at separate visits 6 weeks apart in toddlers aged 12 to 18 months. Primary objective: * To demonstrate the non-inferiority of the antibody responses in terms of seroconversion of the concomitant administration of JE-CV and MMR compared to the antibody responses after the single administration of JE-CV and MMR vaccine. Secondary objectives: * To describe the immune response to JE CV and MMR before and after one dose of JE CV and MMR vaccine, respectively. * To describe the safety of a single dose of JE-CV and MMR vaccine (given separately at a 6-week interval and the safety of the concomitant administration of JE-CV and MMR vaccine in all subjects up to 6 months after last vaccination.

Eligibility Criteria

Inclusion Criteria

Aged 12 to 18 months on the day of inclusion .
Born at full term of pregnancy (≥ 37 weeks) and with a birth weight ≥ 2.5 kg.
Subject in good health based on medical history and physical examination.
Provision of informed consent form signed by at least one parent or other legally acceptable representative, and by an independent witness if the parents or legally acceptable representative cannot read.
Subject and parent/legally acceptable representative or delegate able to attend all scheduled visits and comply with all trial procedures.

Exclusion Criteria

Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination.
Planned participation in another clinical trial during the present trial period.
Receipt of any vaccine in the 4 weeks preceding the first trial vaccination except for pandemic influenza vaccination, which may be received at least two weeks before the study vaccines.
Planned receipt of any vaccine up to the 6 weeks following the last trial vaccination except for pandemic influenza vaccine. In the event of a local or national immunization program with a pandemic influenza vaccine, participants who receive a pandemic influenza vaccine at any time during the trial will not be withdrawn from the trial.
Previous vaccination against measles, measles-mumps-rubella (MMR), or flavivirus disease, including Japanese encephalitis (JE).
Receipt of blood in the past 6 months that might interfere with the assessment of the immune response
Receipt of intravenous injection of plasma, platelet product, or high dose of intravenous immunoglobulin in the past 11 months
Receipt of intramuscular treatment of immunoglobulin or Hepatitis B immunoglobulin in the past 3 months
Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
Known history of human immunodeficiency virus, hepatitis B surface antigen, or hepatitis C seropositivity.
History of measles, mumps, rubella, or flavivirus infection confirmed either clinically, serologically, or microbiologically.
Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to a vaccine containing any of the same substances .
Known systemic hypersensitivity to gelatin, eggs, or anaphylactic/anaphylactoid reaction to neomycin.
Known history of thrombocytopenia.
Administration of any anti-viral within 2 months preceding first vaccination and up to the 6 weeks following the last trial vaccination.
History of central nervous system disorder or disease, including seizures and febrile seizures.
Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01188343). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.